BioNTech Ownership

Who are the major shareholders and have insiders been buying or selling?


Recent Insider Transactions

Insider Trading Volume

Insider Buying: Insufficient data to determine if insiders have bought more shares than they have sold in the past 3 months.


Ownership Breakdown

What is the ownership structure of B1NT34?
Owner TypeNumber of SharesOwnership Percentage
Private Companies1,9800.000826%
Individual Insiders44,128,29318.4%
General Public44,859,44518.7%
Institutions48,260,93320.1%
VC/PE Firms102,489,10142.8%

Dilution of Shares: Shareholders have not been meaningfully diluted in the past year.


Top Shareholders

Top 25 shareholders own 76.25% of the company
OwnershipNameSharesCurrent ValueChange %Portfolio %
42.8%
AT Impf GmbH
102,489,101R$73.9b-1.5%no data
17.2%
Ugur Sahin
41,295,728R$29.8b0%no data
3.47%
Baillie Gifford & Co.
8,308,071R$6.0b0.38%0.41%
2.49%
FMR LLC
5,979,545R$4.3b770%0.04%
1.88%
PRIMECAP Management Company
4,516,518R$3.3b-5.7%0.37%
1.82%
Flossbach & Von Storch Vermoegensmanagement AG
4,359,607R$3.1b-0.45%1.25%
0.86%
BlackRock, Inc.
2,071,934R$1.5b9.31%no data
0.81%
Capital Research and Management Company
1,951,606R$1.4b-0.09%0.01%
0.75%
Temasek Holdings (Private) Limited
1,807,232R$1.3b0%0.18%
0.5%
Salvia GmbH
1,193,651R$860.6m0%no data
0.39%
Candriam, Société En Commandite Par Actions
927,164R$668.4m60.1%0.3%
0.38%
Ozlem Tureci
913,247R$658.4m0%no data
0.34%
Sean Marett
815,263R$587.8m0%no data
0.31%
Sierk Poetting
754,784R$544.2m0%no data
0.27%
Morgan Stanley, Investment Banking and Brokerage Investments
653,618R$471.2m-41.2%0.01%
0.27%
Altrinsic Global Advisors, LLC
652,706R$470.6m-3.48%2.15%
0.26%
Balyasny Asset Management L.P.
620,466R$447.3m36.1%0.19%
0.21%
Fred Alger Management, LLC
500,844R$361.1m0%0.25%
0.2%
Acatis Anlageberatung fur Investmentfonds GmbH
486,632R$350.8m0%3.74%
0.2%
Deka Investment GmbH
481,397R$347.1m12.6%0.05%
0.19%
First Trust Advisors LP
451,192R$325.3m10.3%0.04%
0.17%
Quinn Opportunity Partners LLC
404,500R$291.6m-40.8%4.07%
0.17%
Voloridge Investment Management, LLC
400,306R$288.6m48.3%0.16%
0.16%
Point72 Asset Management, L.P.
389,238R$280.6m-15.7%0.11%
0.16%
Amundi Asset Management SAS
372,756R$268.7m33.6%0.01%

Company Analysis and Financial Data Status

DataLast Updated (UTC time)
Company Analysis2024/12/26 10:57
End of Day Share Price 2024/12/23 00:00
Earnings2024/09/30
Annual Earnings2023/12/31

Data Sources

The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.

PackageDataTimeframeExample US Source *
Company Financials10 years
  • Income statement
  • Cash flow statement
  • Balance sheet
Analyst Consensus Estimates+3 years
  • Forecast financials
  • Analyst price targets
Market Prices30 years
  • Stock prices
  • Dividends, Splits and Actions
Ownership10 years
  • Top shareholders
  • Insider trading
Management10 years
  • Leadership team
  • Board of directors
Key Developments10 years
  • Company announcements

* example for US securities, for non-US equivalent regulatory forms and sources are used.

Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.

Analysis Model and Snowflake

Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.

Learn about the world class team who designed and built the Simply Wall St analysis model.

Industry and Sector Metrics

Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on .

Analyst Sources

BioNTech SE is covered by 29 analysts. 19 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.

AnalystInstitution
Ishan MajumdarBaptista Research
Zhiqiang ShuBerenberg
Etzer DaroutBMO Capital Markets Equity Research